| Autor: |
P., Sneka, K. P., Hamsadwani, V., Sangamithra, Mahalakshmi, Krishnan |
| Zdroj: |
Journal of Pharmaceutical Negative Results; 2022 Special Issue 7, Vol. 13, p2943-2950, 8p |
| Abstrakt: |
Background & Objective: The Covid-19 vaccines in India were introduced after the phase III trial. Though the vaccines have obtained EUA (Emergency Use Authorization) efficacy data and duration of protection is still unknown. This study helps us to understand the vaccine efficacy, sustainability of immune response. Methods: Blood samples and detailed history were collected. Serum sample are collected after 3 months and 6 months after Covishield vaccine to analyze the presence of Anti SARS IgG antibody to S spike protein. Results : Out of the 550 study population, 2% and 16 % had waning antibody titres by 3 months and 6 months respectively after 2 doses of vaccination. Majority of which had co-morbid health conditions (p<0.5) and O +ve blood group people had more secondary vaccine failures. Increasing age had significant association with wanning immunity. Prolonged interval between the 2 doses had positive effect on the sustainability of immune response at 6 months after 2 doses of ChAdOx1 n CoV-19 vaccination. Interpretation & Conclusions : Notable population had waning immunity after 6 months of ChAdOx1 nCoV-19 vaccination. The current recommendation has to be redefined with respect to various factors such as comorbidities and advancing age to obtain maximum vaccine efficacy. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
